24722

Submission of Federal Rules Under the Congressional Review Act

☒ President of the Senate ☐ Speaker of the House of Representatives ☐ GAO

Please fill the circles electronically or with black pen or #2 pencil.

1. Name of Department or Agency
U.S. Nuclear Regulatory Commission

2. Subdivision or Office
FSME

3. Rule Title
Medical Use of Byproduct Material - Authorized User Clarification

4. Regulation Identifier Number (RIN) or Other Unique Identifier (if applicable)
RIN 3150-AI59

5. Major Rule ○ Non-major Rule ◉

6. Final Rule ○ Other ○ _____

7. With respect to this rule, did your agency solicit public comments? Yes ○ No ○ N/A ◉

8. Priority of Regulation (fill in one)
○ Economically Significant; or Significant; or Substantive, Non Significant
◉ Routine and Frequent or Informational/Administrative/Other (Do not complete the other side of this form if filled in above.)

9. Effective Date (if applicable)

10. Concise Summary of Rule (fill in one or both) attached ○ stated in rule ◉

Submitted by: _____ (signature)

Name: **Rebecca Schmidt**

Title: **Director, Office of Congressional Affairs**

For Congressional Use Only:

Date Received: _____

Committee of Jurisdiction: _____

3/23/99

	Yes	No	N/A
A. With respect to this rule, did your agency prepare an analysis of costs and benefits?	○	○	◉
B. With respect to this rule, by the final rulemaking stage, did your agency			
1. certify that the rule would not have a significant economic impact on a substantial number of small entities under 5 U.S.C.§ 605(b)?	○	○	◉
2. prepare a final Regulatory Flexibility Analysis under 5 U.S.C. § 604(a)?	○	○	◉
C. With respect to this rule, did your agency prepare a written statement under § 202 of the Unfunded Mandates Reform Act of 1995?	○	○	◉
D. With respect to this rule, did your agency prepare an Environmental Assessment or an Environmental Impact Statement under the National Environmental Policy Actg (NEPA)?	○	○	◉
E. Does this rule contain a collection of information requiring OMB approval under the Paperwork Reduction Act of 1995?	○	○	◉
F. Did you discuss any of the following in the preamble to the rule?	○	○	◉
• E.O. 12612, Federalism	○	○	◉
• E.O. 126630, Government Actions and Interference with Constitutionally Protected Property Rights	○	○	◉
• E.O. 12866, Regulatory Planning and Review	○	○	◉
• E.O. 12875, Enhancing the Intergovernmental Partnership	○	○	◉
• E.O. 12988, Civil Justice Reform	○	○	◉
• E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks	○	○	◉
• Other statutes or executive orders discussed in the preamble concerning the rulemaking process (please specify)			

24722

Submission of Federal Rules Under the Congressional Review Act

☐ President of the Senate ☒ Speaker of the House of Representatives ☐ GAO

Please fill the circles electronically or with black pen or #2 pencil.

1. Name of Department or Agency
U.S. Nuclear Regulatory Commission

2. Subdivision or Office
FSME

3. Rule Title
Medical Use of Byproduct Material - Authorized User Clarification

4. Regulation Identifier Number (RIN) or Other Unique Identifier (if applicable)
RIN 3150-AI59

5. Major Rule ○ Non-major Rule ◉

6. Final Rule ○ Other ○ _____

7. With respect to this rule, did your agency solicit public comments? Yes ○ No ○ N/A ◉

8. Priority of Regulation (fill in one)
○ Economically Significant; or Significant; or Substantive, Non Significant
◉ Routine and Frequent or Informational/Administrative/Other (Do not complete the other side of this form if filled in above.)

9. Effective Date (if applicable)

10. Concise Summary of Rule (fill in one or both) attached ○ stated in rule ◉

Submitted by: _____ (signature)

Name: **Rebecca Schmidt**

Title: **Director, Office of Congressional Affairs**

For Congressional Use Only:

Date Received: _____

Committee of Jurisdiction: _____

	Yes	No	N/A
A. With respect to this rule, did your agency prepare an analysis of costs and benefits?	○	○	◉
B. With respect to this rule, by the final rulemaking stage, did your agency			
1. certify that the rule would not have a significant economic impact on a substantial number of small entities under 5 U.S.C.§ 605(b)?	○	○	◉
2. prepare a final Regulatory Flexibility Analysis under 5 U.S.C. § 604(a)?	○	○	◉
C. With respect to this rule, did your agency prepare a written statement under § 202 of the Unfunded Mandates Reform Act of 1995?	○	○	◉
D. With respect to this rule, did your agency prepare an Environmental Assessment or an Environmental Impact Statement under the National Environmental Policy Actg (NEPA)?	○	○	◉
E. Does this rule contain a collection of information requiring OMB approval under the Paperwork Reduction Act of 1995?	○	○	◉
F. Did you discuss any of the following in the preamble to the rule?	○	○	◉
• E.O. 12612, Federalism	○	○	◉
• E.O. 126630, Government Actions and Interference with Constitutionally Protected Property Rights	○	○	◉
• E.O. 12866, Regulatory Planning and Review	○	○	◉
• E.O. 12875, Enhancing the Intergovernmental Partnership	○	○	◉
• E.O. 12988, Civil Justice Reform	○	○	◉
• E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks	○	○	◉
• Other statutes or executive orders discussed in the preamble concerning the rulemaking process (please specify)			

24722

Submission of Federal Rules Under the Congressional Review Act

☐ President of the Senate ☐ Speaker of the House of Representatives ☒ GAO

Please fill the circles electronically or with black pen or #2 pencil.

1. Name of Department or Agency
U.S. Nuclear Regulatory Commission

2. Subdivision or Office
FSME

3. Rule Title
Medical Use of Byproduct Material - Authorized User Clarification

4. Regulation Identifier Number (RIN) or Other Unique Identifier (if applicable)
RIN 3150-AI59

5. Major Rule ○ Non-major Rule ◉

6. Final Rule ○ Other ○ _____

7. With respect to this rule, did your agency solicit public comments? Yes ○ No ○ N/A ◉

8. Priority of Regulation (fill in one)
○ Economically Significant; or Significant; or Substantive, Non Significant
◉ Routine and Frequent or Informational/Administrative/Other (Do not complete the other side of this form if filled in above.)

9. Effective Date (if applicable)

10. Concise Summary of Rule (fill in one or both) attached ○ stated in rule ◉

Submitted by: _____ (signature)

Name: **Rebecca Schmidt**

Title: **Director, Office of Congressional Affairs**

For Congressional Use Only:

Date Received: _____

Committee of Jurisdiction: _____

3/23/99

	Yes	No	N/A
A. With respect to this rule, did your agency prepare an analysis of costs and benefits?	○	○	◉
B. With respect to this rule, by the final rulemaking stage, did your agency			
1. certify that the rule would not have a significant economic impact on a substantial number of small entities under 5 U.S.C.§ 605(b)?	○	○	◉
2. prepare a final Regulatory Flexibility Analysis under 5 U.S.C. § 604(a)?	○	○	◉
C. With respect to this rule, did your agency prepare a written statement under § 202 of the Unfunded Mandates Reform Act of 1995?	○	○	◉
D. With respect to this rule, did your agency prepare an Environmental Assessment or an Environmental Impact Statement under the National Environmental Policy Actg (NEPA)?	○	○	◉
E. Does this rule contain a collection of information requiring OMB approval under the Paperwork Reduction Act of 1995?	○	○	◉
F. Did you discuss any of the following in the preamble to the rule?	○	○	◉
• E.O. 12612, Federalism	○	○	◉
• E.O. 126630, Government Actions and Interference with Constitutionally Protected Property Rights	○	○	◉
• E.O. 12866, Regulatory Planning and Review	○	○	◉
• E.O. 12875, Enhancing the Intergovernmental Partnership	○	○	◉
• E.O. 12988, Civil Justice Reform	○	○	◉
• E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks	○	○	◉
• Other statutes or executive orders discussed in the preamble concerning the rulemaking process (please specify)			